Incyte (NASDAQ:INCY) Posts Earnings Results, Beats Expectations By $0.33 EPS

Key Points

• Incyte beat quarterly expectations: Revenue rose 14% year over year to $1.56 billion, exceeding estimates of $1.46 billion, while its adjusted loss of $3.60 per share was $0.33 better than expected.
• Growth products supported higher guidance: Opzelura sales increased 36% to $255 million, and Incyte raised its 2026 net-sales outlook to $5.21 billion–$5.30 billion.
• Investment costs remain a risk: A $1.23 billion Vega acquisition-related research charge drove a GAAP loss, while pipeline pruning and relatively modest Jakafi growth weighed on the outlook; shares fell 1.5% after the report.

Incyte (NASDAQ:INCY - Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts' consensus estimates of ($3.93) by $0.33, FiscalAI reports. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The firm had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. During the same period in the previous year, the business posted $2.26 EPS. The business's quarterly revenue was up 14.0% on a year-over-year basis.

Here are the key takeaways from Incyte's conference call:

• Strong quarterly performance and raised guidance: Third-quarter revenue and net sales both increased 14% year over year to $1.56 billion and $1.32 billion, respectively. Incyte raised full-year 2026 net sales guidance to $5.21 billion–$5.30 billion, driven by OPZELURA and hematology/oncology products.
• OPZELURA continued to drive growth: OPZELURA sales rose 36% to $255 million, with underlying U.S. demand up 24% on a pro forma basis and strong new-patient growth. European approval for moderate atopic dermatitis and potential additional HS applications could further expand the franchise.
• Late-stage pipeline advanced across multiple therapeutic areas: Incyte highlighted encouraging early data for its G12D inhibitor in pancreatic and colorectal cancer and its TGFβR2×PD-1 bispecific in colorectal cancer. The company now has six Phase III programs and expects additional data and regulatory milestones over the next 12–18 months.
• CALR-directed MPN program remains a major value driver: Management expects to present more mature frontline data for INCA033989 at ASH and plans to advance a potentially more potent, longer-acting next-generation CALR antibody into the clinic in early 2027. The company is also discussing alternative composite endpoints with the FDA that could better capture disease modification.
• Pipeline investment and portfolio pruning create near-term risks: GAAP operating expenses surged 146%, largely due to the $1.23 billion Vega acquisition-related R&D charge, while the company discontinued enrollment in the Phase III platinum-resistant ovarian cancer study for its CDK2 inhibitor. Jakafi sales grew only 4% because of pricing effects, and management continues to prepare for retaining only 10%–30% of the franchise by 2029.

Incyte Stock Down 1.5%

Shares of NASDAQ:INCY traded down $1.71 during midday trading on Thursday, hitting $115.16. 1,891,232 shares of the stock traded hands, compared to its average volume of 1,727,621. The business's 50 day moving average is $120.86 and its two-hundred day moving average is $108.02. The stock has a market capitalization of $23.34 billion, a PE ratio of 14.67, a P/E/G ratio of 4.79 and a beta of 0.74. Incyte has a one year low of $89.25 and a one year high of $132.60.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Revenue exceeded estimates: Third-quarter total revenue rose 14% year over year to $1.56 billion, above the roughly $1.46 billion consensus estimate. Total net sales increased 14% to $1.32 billion. Incyte Posts Loss In Q3, But Revenue Rises; Lifts Sales Outlook
• Positive Sentiment: Key products continued to grow: Opzelura sales climbed 36% to $255 million, while Hematology and Oncology portfolio sales rose 38% to $235 million. Jakafi and Jakafi XR sales increased 4% to $827 million. Incyte Reports $1.56 Billion Third-Quarter Revenue and Raises 2026 Sales Guidance
• Positive Sentiment: Sales outlook was raised: Incyte increased its 2026 total net-sales guidance to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously, also raising its outlook for Opzelura and Hematology and Oncology sales. Adjusted EPS of $3.60 loss beat the consensus estimate of a $3.93 loss. Incyte Reports Q3 Loss, Beats Revenue Estimates
• Neutral Sentiment: Pipeline progress: Adagene dosed the first patient in a Phase 1 study combining its muzastotug with Incyte’s INCA33890 for microsatellite-stable colorectal cancer. The early-stage program adds potential long-term value but is not an immediate revenue driver. Adagene Announces Dosing of First Patient
• Negative Sentiment: Large acquisition charge drove the loss: Incyte recorded a $1.23 billion in-process research and development expense related to its Vega Therapeutics acquisition, contributing to a GAAP net loss of approximately $785 million, or $3.86 per share, compared with earnings of $2.26 per share a year earlier. Incyte Corporation Reports Earnings Results
• Negative Sentiment: Guidance may still disappoint investors: Although Incyte raised its sales range, reports indicate the new full-year outlook remained significantly below heightened analyst expectations, potentially limiting the benefit of the quarterly revenue beat. Incyte’s Q3 2026 Sales Beat Estimates

Analyst Ratings Changes

A number of brokerages recently commented on INCY. Citigroup reiterated a "buy" rating on shares of Incyte in a research report on Monday, August 3rd. Royal Bank Of Canada upped their price target on shares of Incyte from $109.00 to $114.00 and gave the company a "sector perform" rating in a research report on Thursday, October 8th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Incyte in a research note on Tuesday. Wells Fargo & Company lifted their price objective on Incyte from $116.00 to $128.00 and gave the stock an "equal weight" rating in a report on Thursday, October 1st. Finally, JPMorgan Chase & Co. boosted their target price on Incyte from $120.00 to $123.00 and gave the company a "neutral" rating in a research note on Monday, September 28th. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $131.43.

Insider Activity

In related news, EVP Patrick Mayes sold 41,899 shares of the firm's stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total value of $5,005,254.54. Following the sale, the executive vice president directly owned 61,441 shares of the company's stock, valued at $7,339,741.86. This trade represents a 40.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 2,642 shares of the business's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $112.71, for a total value of $297,779.82. Following the transaction, the insider owned 183,200 shares in the company, valued at approximately $20,648,472. This represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 55,342 shares of company stock worth $6,659,208 over the last three months. 16.20% of the stock is owned by insiders.

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.